Purchase this article with an account.
Kira Segal, Michelle Lee, Kristin Chapman, Mark Rosenblatt, Kimberly Sippel, Christopher Starr, Jessica Ciralsky, Weill Cornell Eye Associates; Prosthetic Replacement of the Ocular Surface Ecosystem (PROSE) Treatment: A Partner Clinic Experience. Invest. Ophthalmol. Vis. Sci. 2013;54(15):5485.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
PURPOSE: To evaluate demographics, clinical course, and outcomes of patients who received the PROSE device at a partner clinic.
METHODS: Retrospective chart review of 37 consecutive patients (66 eyes) fit with the PROSE device.
RESULTS: Indications for PROSE treatment included ectasia in 17 eyes (25.8%) and ocular surface disease in 49 eyes (74.2%). The average follow-up time was 4.76 months (2.4-9.35). Visual acuity improved with the PROSE device a statistically significant amount (p=0.002). All patients had improved ocular symptoms and decreased reliance on topical lubricants.
CONCLUSIONS: PROSE is an effective treatment option for many patients with complex corneal diseases.
This PDF is available to Subscribers Only